Briggs Morrison, M.D., Joins CRISPR Therapeutics to Propel Innovation in Gene Editing

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced it ...

January 08, 2025 | Wednesday | News
TC BioPharm Shareholders Approve 25% Stock Dividend, Reinforcing Strong Financial Outlook

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic ...

January 07, 2025 | Tuesday | News
Viracta Therapeutics Initiates Strategic Review and Halts NAVAL-1 Trial to Conserve Resources

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancer...

December 27, 2024 | Friday | News
Wolfgang Wienand, CEO of Lonza, Outlines ‘One Lonza’ Strategy and 2025 Growth Targets

Lonza has provided an overview of its new “One Lonza” strategy and new organizational structure As Lonza focuses on its core CDMO1 busines...

December 12, 2024 | Thursday | News
Roche Presents Promising Data on Columvi® and Lunsumio® at ASH 2024, Advancing Treatment for Lymphoma

Roche (SIX: RO, ROG; OTCQX: RHHBY) that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presente...

December 11, 2024 | Wednesday | News
bluebird bio Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Listing Compliance

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) announced that it will proceed with a 1-for-20 reverse stock sp...

December 09, 2024 | Monday | News
Amgen Presents New Data on UPLIZNA and KRYSTEXXA at ACR Convergence 2024

Amgen (NASDAQ:AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheum...

November 15, 2024 | Friday | News
GSK’s Blenrep Combination Demonstrates Significant Survival Benefit in Relapsed/Refractory Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...

November 15, 2024 | Friday | News
Bio-Rad Advances Oncology Diagnostics with IVDR Certification for CML Assay and Strategic Collaborations in MRD and ctDNA Detection

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced updates on its onco...

November 13, 2024 | Wednesday | News
AstraZeneca and Amgen’s Tezspire Shows Promising Phase III WAYPOINT Trial Results in Chronic Rhinosinusitis with Nasal Polyps

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that...

November 11, 2024 | Monday | News
Gilead Sciences to Present Groundbreaking HIV Research at HIV Glasgow 2024, Highlighting Advances in Treatment and Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...

November 08, 2024 | Friday | News
Poseida Therapeutics to Present New Preclinical Data and Clinical Insights at SITC and ASH 2024

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral t...

November 06, 2024 | Wednesday | News
Theriva Biologics Named Finalist for Merck KGaA’s EMEA Advance Biotech Grant

Theriva™ Biologics (NYSE American: TOVX), a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and relate...

November 04, 2024 | Monday | News
Bristol Myers Squibb to Present New Data on COBENFY™ for Schizophrenia at Psych Congress 2024

Bristol Myers Squibb (NYSE: BMY) announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio...

October 29, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close